News
03-07-2016, 06:31 AM
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
More... (http://www.news-medical.net/news/20160307/New-FDA-approval-expands-use-of-AstraZenecas-Faslodex-for-women-with-HR2b-HER2-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20160307/New-FDA-approval-expands-use-of-AstraZenecas-Faslodex-for-women-with-HR2b-HER2-metastatic-breast-cancer.aspx)